Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pharma Mar, S.A
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
A Phase II Study of Plitidepsin in Patients with Angioimmunoblastic T-cell Lymphoma. Estudio de fase II de plitidepsin en pacientes con linfoma angioinmunoblástico de células T
To evaluate the efficacy of plitidepsin on the basis of overall response rate (ORR) in patients with relapsing/refractory angioimmunoblastic T-cell lymphoma (AITL). Evaluar la eficacia de plitid...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma
To compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone as measured by progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (M...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS)
To evaluate the efficacy of trabectedin vs. standard DXCT as first-line treatment of patients with advanced TRS, by comparing PFS in each treatment arm.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
The objective of this study is to assess the potential effects of trabectedin on the QT/QTc interval duration measured by electrocardiograms (ECGs) in subjects with advanced solid tumor malignancies w...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Efficacité et Tolérance de la Plitidepsine chez les patients souffrant d’un liposarcome dédifférencié (DLPS) avancé, non opérable ou métastatique, en rechute/réfractaire : Une étude exploratoire multicentrique de phase II
To evaluate the antitumor activity of plitidepsin in terms of progression-free survival rate at three months (PFS3).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Phase II Trial of Plitidepsin (Aplidin®) in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to bortezomib and lenalidomide . Ensayo Fase II de Plitidepsin (Aplidin®) en Combinación con Bortezomib y Dexametasona en Pacientes con Mieloma Múltiple Doble Refractario a bortezomib y lenalidomida
To evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with multiple myeloma (MM) double refractory to bortezomib and lenalidomide in terms of overall res...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcoma
- To determine the pathological complete response (pCR) rate with trabectedin in patients with locally advanced (Stage III) myxoid / round cell liposarcoma (MRCL).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoral basada en Platino en Pacientes con Cáncer No Microcítico de Pulmón (CNMP) Avanzado con Sobreexpresión de XPG y/o ERCC1, y Subexpresión de BRCA1
Evaluar la eficacia de trabectedina en pacientes con CNMP y que presenten sobreexpresión de ERCC1 y/o XPG, y baja expresión de BRCA1, después de fallo al tratamiento estándar basado en platino. Para e...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Phase II multicenter,open-label, clinical and pharmacokinetic study of Aplidin® as a 3-hour infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the urothelium, relapsing or progressing after first line chemotherapy
To assess the anti-tumor activity of Aplidin® administered as a 3 h iv infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the urothelium, relapsing or progr...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Pharma Mar, S.A
Update Il y a 4 ans
Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers
Primary Objective: to determine the objective response rate by RECIST (Complete and Partial Response [CR + PR]) with trabectedin in patients with the following metastatic breast cancer subtypes: Group...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
Next